Article Details
Retrieved on: 2021-06-08 21:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities upped their price objective on shares of NovoCure from $132.00 to $142.00 and gave the company a "hold" rating in a research note ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here